Takeda Pharmaceutical Co. reported positive results from their Phase 3 studies on zasocitinib, showing over 50% of patients achieved clear or nearly clear skin for psoriasis by week 16. The filing is significant as it highlights a potential new treatment for psoriasis, contributing to future revenue growth.